Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
National Institutes of Health
Free. Verify your email, then we send one reminder only.
- Posted
- Oct 23, 2025
- Amount
- $50,000 - $150,000
- Closes
- Nov 10, 2026 (in 104 days)
Classification and identifiers
- Solicitation number
- RFA-CA-27-001
- Assistance listing (CFDA)
- 93.394
Amount
$50,000 - $150,000
Who can apply
Public colleges and universities, Local government agencies, and State government agencies can all apply here. Check the eligibility details below to see if your organization fits.
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
About this opportunity
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to develop innovative technologies offering new capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens for basic, clinical, or epidemiological cancer research. The NOFO solicits R61 applications for early-stage projects proposing proof-of-concept/pilot studies to test the technical feasibility of the proposed method, tool, assay, platform, or instrument. Technologies proposed for development may have potential for widespread applicability but must be focused for this program on cancer-relevant use cases. Projects proposing to apply or use existing technologies for hypothesis-driven research w...
Related opportunities
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)National Institutes of HealthCloses Nov 2026Up to $300K
- NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)National Institutes of HealthCloses Apr 2027
- Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)National Institutes of HealthCloses Nov 2028